Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish National Diabetes Register
Open accessThe DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index, and 1 are not checked yet.
Abstract
Objective: To evaluate the effectiveness and safety of metformin use in clinical practice in a large sample of pharmacologically treated patients with type 2 diabetes and different levels of renal function. Design: Observational study between July 2004 and December 2010, mean follow-up 3.9 years. Setting: Hospital outpatient clinics and primary care in Sweden. Participants: 51 675 men and women with type 2 diabetes, registered in the Swedish National Diabetes Register, and on continuous glucose-lowering treatment with oral hypoglycaemic agents (OHAs) or insulin. Main outcome measures: Risks of cardiovascular disease (CVD), all-cause mortality and acidosis/serious infection, associated with each treatment regimens, were analysed in all patients and in subgroups with different estimated glomerular filtration rate (eGFR) intervals. Covariance adjustment and propensity scores were used to adjust for several baseline risk factors and characteristics at Cox regression. Results: Compared with metformin in monotherapy, HRs for fatal/non-fatal CVD and all-cause mortality with all other OHAs combined (approximately 80% sulphonylureas) in monotherapy were 1.02 (95% CI 0.93 to 1.12) and 1.13 (1.01 to 1.27), while 1.18 (1.07 to 1.29) and 1.34 (1.19 to 1.50) with insulin in monotherapy, adjusting using propensity scores. Metformin, compared with any other treatment, showed reduced risks of acidosis/serious infection (adjusted HR 0.85, 95% CI 0.74 to 0.97) and all-cause mortality (HR 0.87, 95% CI 0.77 to 0.99), in patients with eGFR 45–60 ml/min/1.73 m 2 , and no increased risks of all-cause mortality, acidosis/serious infection or CVD were found in patients with eGFR 30–45 ml/min/1.73 m 2 . Conclusions: Metformin showed lower risk than insulin for CVD and all-cause mortality and slightly lower risk for all-cause mortality compared with other OHA, in these 51 675 patients followed for 4 years. Patients with renal impairment showed no increased risk of CVD, all-cause mortality or acidosis/serious infection. In clinical practice, the benefits of metformin use clearly outbalance the risk of severe side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Concerns regarding lactic acidosis have not been substantiated.558,559”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [559]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T., Rogers, N., Roth, D., & for the Modification of Diet in Renal Disease Study Group* (1999) · Annals of Internal Medicine · doi:10.7326/0003-4819-130-6-199903160-00002 · Cited by 15,079
10-year follow-up of intensive glucose control in type 2 diabetes
Holman, R. R., Paul, S. K., Bethel, M. A., Matthews, D. R., & Neil, H. A. W. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0806470 · Cited by 7,751 · cited 1×
“The UKPDS demonstrated a reduction in all-cause mortality in the subgroup of obese DM2 patients treated with metformin compared with diet, SU or insulin,(2) also confirmed in a 10-year post-interventional follow-up.(3) Furthermore, several recent observational studies have reported reduced risk with metformin compared…”
ResultProportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885 · cited 1×
“Additional checks of the form of the time dependence were made using plots of scaled Schoenfeld residuals.(27) All statistical analyses were performed with SAS V.”
MethodGlobal and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883 · cited 1×
“INTRODUCTION Type 2 diabetes mellitus (DM2) is a common disease, which causes major morbidity and mortality due to micro- and macrovascular complications.(1) A range of glucose-lowering To cite: Ekström N, Schiöler L, Svensson A-M, et al.”
BackgroundCardiovascular Morbidity and Mortality Associated With the Metabolic Syndrome
Isomaa, B., Almgren, P., Tuomi, T., Forsén, B., Lahti, K., Nissén, M., Taskinen, M.-R., & Groop, L. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.683 · Cited by 4,760
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Tunstall-Pedoe, H., Kuulasmaa, K., Amouyel, P., Arveiler, D., Rajakangas, A. M., & Pajak, A. (1994) · Circulation · doi:10.1161/01.cir.90.1.583 · Cited by 2,263
Cited by
Items 101–200 of 223
Relationship between metformin and frailty syndrome in elderly people with type 2 diabetes.
Sumantri, S., Setiati, S., Purnamasari, D., & Dewiasty, E. (2014) · Acta medica Indonesiana · Cited by 33
Metformin prevents stroke damage in non-diabetic female mice with chronic kidney disease
Grissi, M., Boudot, C., Assem, M., Candellier, A., Lando, M., Poirot, S., Boullier, A., Bennis, Y., Lenglet, G., Avondo, C., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-86905-9 · Cited by 22
Buzea, A., Manu, P., Dima, L., & Correll, C. U. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2147425 · Cited by 20
Oral glucose lowering drugs in type 2 diabetic patients with chronic kidney disease
Nogueira, C., Souto, S. B., Vinha, E., Braga, D. C., & Carvalho, D. M. (2013) · HORMONES · doi:10.14310/horm.2002.1436 · Cited by 21
Risk & Prevention Collaborative Group, Marzona, I., Avanzini, F., Lucisano, G., Tettamanti, M., Baviera, M., Nicolucci, A., & Roncaglioni, M. C. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0899-0 · Cited by 20
Metformin—mechanisms of its glycemia-reducing effect
Drewe, J., Foretz, M., & Krähenbühl, S. (2025) · Pharmacological Reviews · doi:10.1016/j.pharmr.2025.100106 · Cited by 19
Tan, K., Simpson, A., Huang, S., Tang, B. M. P., McLean, A. S., & Nalos, M. (2019) · Critical Care Explorations · doi:10.1097/cce.0000000000000009 · Cited by 20
Elnaem, M. H., Mansour, N. O., Nahas, A. R. F., Baraka, M. A., Elkalmi, R. M., & Cheema, E. U. (2020) · International Journal of General Medicine · doi:10.2147/ijgm.s285191 · Cited by 20
Anti-tumour effect of metformin in canine mammary gland tumour cells
Saeki, K., Watanabe, M., Tsuboi, M., Sugano, S., Yoshitake, R., Tanaka, Y., Ong, S. M., Saito, T., Matsumoto, K., Fujita, N., et al. (2015) · The Veterinary Journal · doi:10.1016/j.tvjl.2015.04.026 · Cited by 20
Qi, Y., Zhu, J., & Liu, W.-X. (2020) · BMC Cardiovascular Disorders · doi:10.1186/s12872-020-01474-5 · Cited by 17
Improving Postapproval Drug Safety Surveillance: Getting Better Information Sooner
Hennessy, S., & Strom, B. L. (2014) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135955 · Cited by 17
Is metformin a geroprotector? A peek into the current clinical and experimental data
Zajda, A., Huttunen, K. M., Sikora, J., Podsiedlik, M., & Markowicz-Piasecka, M. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111350 · Cited by 16
Liu, P., Pan, Y., Song, Y., Zhou, Y., Zhang, W., Li, X., Li, J., Li, Y., & Ma, L. (2023) · European journal of medical research · doi:10.1186/s40001-023-01017-6 · Cited by 16
Instituting a successful discharge plan for patients with type 2 diabetes: challenges and solutions
Demidowich, A. P., Batty, K., & Zilbermint, M. (2022) · Diabetes Spectrum · doi:10.2337/dsi22-0013 · Cited by 15
Ulrichsen, S. P., Mor, A., Svensson, E., Larsen, F. B., & Thomsen, R. W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0111849 · Cited by 15
Still sour about lactic acidosis years later: role of metformin in heart failure
Kuan, W., Beavers, C. J., & Guglin, M. E. (2017) · Heart Failure Reviews · doi:10.1007/s10741-017-9649-9 · Cited by 15
Using registries to identify type 2 diabetes patients
Schlosser, & Sørensen, H. T. (2014) · Clinical Epidemiology · doi:10.2147/clep.s75572 · Cited by 14
A single-arm pilot study of metformin in patients with autosomal dominant polycystic kidney disease
Sorohan, B. M., Ismail, G., Andronesi, A. G., Micu, G., Obrișcă, B., Jurubiță, R. A., Sinescu, I. C., & Baston, C. (2019) · BMC Nephrology · doi:10.1186/s12882-019-1463-2 · Cited by 15
Karlsson, S. A., Hero, C., Eliasson, B., Franzén, S., Svensson, A., Miftaraj, M., Guðbjörnsdóttir, S., Eeg‐Olofsson, K., & Sundell, K. A. (2017) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.4281 · Cited by 14
Self-citationMetformin: clinical topics and new mechanisms of action
Fujita, Y., & Inagaki, N. (2016) · Diabetology International · doi:10.1007/s13340-016-0300-0 · Cited by 14
Risk of metformin use in patients with T2DM and advanced CKD
Schernthaner, G., & Schernthaner-Reiter, M. H. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.132 · Cited by 14
Álvarez, C. A., Halm, E. A., Pugh, M. J., McGuire, D. K., Hennessy, S., Miller, R. T., Lingvay, I., Vouri, S. M., Zullo, A. R., Yang, H., et al. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.170 · Cited by 14
Correia, M. S., & Horowitz, B. Z. (2022) · Clinical Toxicology · doi:10.1080/15563650.2022.2127363 · Cited by 13
Improved prognosis in gastric adenocarcinoma among metformin users in a population-based study
Zheng, J., Santoni, G., Xie, S.-H., & Lagergren, J. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01408-8 · Cited by 14
Huang, D. L., Abrass, I. B., & Young, B. A. (2014) · BMC Nephrology · doi:10.1186/1471-2369-15-86 · Cited by 13
Metformin Use in Type 2 Diabetes Mellitus With CKD: Is It Time to Liberalize Dosing Recommendations?
Stanton, R. C. (2015) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.04.001 · Cited by 13
Aberrant HSF1 signaling activation underlies metformin amelioration of myocardial infarction in mice
Wang, M., Zou, J., Wang, J., Liu, M., Liu, K., Wang, N., & Wang, K. (2022) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2022.07.009 · Cited by 12
Treatment of Type 2 Diabetes Mellitus in the Older Adult: A Review
Pratley, R. E., Heller, S. R., & Miller, M. A. (2014) · Endocrine Practice · doi:10.4158/ep13192.ra · Cited by 13
Monitoring Patients on Metformin: Recent Changes and Rationales
Wooley, A. C., & Kerr, J. L. (2017) · Journal of Pharmacy Technology · doi:10.1177/8755122517747295 · Cited by 14
Metformin Indications, Dosage, Adverse Reactions, and Contraindications
Stoica, R. A., Ștefan, D. S., Rizzo, M., Suceveanu, A., Suceveanu, A. P., Serafinceanu, C., & Stoian, A. P. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.88675 · Cited by 17
Kim, M. H., Oh, H. J., Kwon, S. H., Jeon, J. S., Noh, H., Han, D. C., Kim, H., & Ryu, D. (2021) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.20.222 · Cited by 11
Trinkley, K. E., Anderson, H. D., Nair, K. V., Malone, D. C., & Saseen, J. J. (2018) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622318779760 · Cited by 11
Treating Patients With Diabetes of Long Duration: GLP-1 Receptor Agonists and Insulin in Combination
Moghissi, E. S. (2014) · Journal of Osteopathic Medicine · doi:10.7556/jaoa.2014.086 · Cited by 10
Becquemont, L., Bauduceau, B., Benattar‐Zibi, L., Al‐Salameh, A., Berrut, G., Bertin, P., Bucher, S., Corruble, E., Danchin, N., Dérumeaux, G., et al. (2015) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12526 · Cited by 11
Trends in metformin utilisation and dose appropriateness in Australia
Moon, J. H., Kumar, S. S., Graham, G. G., Baysari, M. T., Williams, K. M., Chen, W., Viardot, A., Greenfield, J. R., & Day, R. O. (2016) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-016-2117-y · Cited by 10
New advances in perioperative cardioprotection
Momeni, M., & Hert, S. G. D. (2019) · F1000Research · doi:10.12688/f1000research.17184.1 · Cited by 12
Fadini, G. P., Frison, V., Simioni, N., Lapolla, A., Gatti, A., Bossi, A. C., Buono, A. D., Fornengo, P., Gottardo, L., Laudato, M., et al. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.119.012244 · Cited by 10
Gentile, S., The AMD-Annals Study Group, Piscitelli, P. A., Viazzi, F. C., Russo, G. T., Ceriello, A., Giorda, C. B., Guida, P., Fioretto, P., Pontremoli, R., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.18816 · Cited by 10
Singh, A. K., Misra, A., Das, A. K., Behl, A., Srivastava, A., Paneerselvam, A., Chidambaram, B., Saboo, B., Sethi, B. K., Makkar, B. M., et al. (2023) · Journal of the Association of Physicians of India · doi:10.59556/japi.71.0422 · Cited by 12
Walz, L., Jönsson, A. K., Ahlner, J., Östgren, C. J., & Druid, H. (2019) · Forensic Science International · doi:10.1016/j.forsciint.2019.109935 · Cited by 9
Clegg, L. E., Jing, Y., Penland, R. C., Boulton, D. W., Hernandez, A. F., Holman, R. R., & Vora, J. P. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14313 · Cited by 9
Wallerstedt, S. M., & Hoffmann, M. (2017) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.13206 · Cited by 11
Campbell, J. M., Adanichkin, N., Kurmis, R., & Munn, Z. (2017) · Burns · doi:10.1016/j.burns.2017.09.013 · Cited by 8
Antidiabetic medication use in patients with type 2 diabetes and chronic kidney disease
Rhee, J. J., Han, J., Montez‐Rath, M. E., Kim, S. H., Cullen, M. R., Stafford, R. S., Winkelmayer, W. C., & Chertow, G. M. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.107423 · Cited by 8
Moyad, M. A., & Vogelzang, N. J. (2014) · Asian Journal of Andrology · doi:10.4103/1008-682x.148070 · Cited by 7
Could metformin be used in patients with diabetes and advanced chronic kidney disease?
Chowdhury, T. A., Srirathan, D., Abraham, G., Oei, E. L., Fan, S. L., McCafferty, K., & Yaqoob, M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12799 · Cited by 8
Rim, J. G., Gallini, J. W., Jasien, C. L., Cui, X., Phillips, L., Trammell, A. W., & Sadikot, R. T. (2022) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2022.01.003 · Cited by 7
Sepahi, M. A., Bhaskar, L. V., Kellner, S., & Valizadeh, R. (2019) · Journal of Nephropathology · doi:10.15171/jnp.2020.04 · Cited by 6
Lactate Levels and Risk of Lactic Acidosis with Metformin in Diabetic Kidney Disease Patients
Bipi, P., George, J., Gomathy, S., Gracious, N., Kumar, S., & Mohandas, M. (2017) · Saudi Journal of Kidney Diseases and Transplantation · doi:10.4103/1319-2442.220870 · Cited by 7
Migdalis, I. N., Παπάνας, Ν., Ioannidis, I., Sotiropoulos, A., Raptis, A. E., Dimitriadis, G., & (HDNS), O. B. O. T. H. D. N. S. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10102104 · Cited by 7
Things we do for no reason™: Routinely holding metformin in the hospital
Cohen, D. A., Ricotta, D. N., & Parikh, P. D. (2021) · Journal of Hospital Medicine · doi:10.12788/jhm.3644 · Cited by 6
Evolving Concepts of Type 2 Diabetes Management
Abushamat, L. A., & Reusch, J. E. B. (2021) · Medical Clinics of North America · doi:10.1016/j.mcna.2021.06.003 · Cited by 7
Investigation of Risk Factors Affecting Lactate Levels in Japanese Patients Treated with Metformin
Yokoyama, S., Tsuji, H., Hiraoka, S., & Nishihara, M. (2016) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b16-00517 · Cited by 7
Maciejczyk, A., & Niemczyk, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47090715 · Cited by 5
The Role of Insulin Resistance in Cardiorenal Metabolic Syndrome
Xiao, J., Song, W. L., Huang, Y., He, X., Weng, Y., & Yu, H. (2025) · Cardiology in Review · doi:10.1097/crd.0000000000001048 · Cited by 5
Barsotti, G. C., Luciano, R. L., Kumar, A., Meliambro, K. A., Kakade, V. R., Tokita, J. E., Naik, A. S., Fu, J., Peck, E. K., Pell, J. F., et al. (2024) · Kidney International Reports · doi:10.1016/j.ekir.2024.02.006 · Cited by 5
Shabil, M., Bushi, G., Yadav, A., Ahmed, M., Kishore, J., Lekamwasam, S., & Joshi, A. (2023) · The Evidence · doi:10.61505/evidence.2023.1.1.3 · Cited by 5
Clarifying the relationship between metformin, acute kidney injury and lactic acidosis
Bell, S., Soto‐Pedre, E., Connelly, P. J., Livingstone, S. J., & Pearson, E. R. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.172 · Cited by 5
Tan, F. C. J. H., Ang, S. B., & Bee, Y. M. (2021) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.2020464 · Cited by 5
厚, 荒., & Ito, H. (2018) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.55.1 · Cited by 5
Ichihara, N., Maezawa, M., Nakao, S., Miyasaka, K., Hirofuji, S., Yamashita, M., Nokura, Y., Matsui, K., Uranishi, H., Kitamura, M., et al. (2024) · BPB Reports · doi:10.1248/bpbreports.7.3_76 · Cited by 4
MALAdaptive: Do We Avoid Metformin Unnecessarily?
Terpening, C. M. (2014) · The Journal of the American Board of Family Medicine · doi:10.3122/jabfm.2014.01.120173 · Cited by 4
Acidosis láctica por metformina. Reporte de dos casos
Ríos, J. F. N., Roldán, D. M., Bolivariana, U. P., Serna-Higuita, L. M., Ocampo-Kohn, C., Aristizábal-Alzate, A., & Zuluaga-Valencia, G. (2018) · IATREIA · doi:10.17533/udea.iatreia.v31n2a07 · Cited by 5
Metformin Associated Lactic Acidosis in Clinical Practice – A Case Series
Schädle, P., Tschritter, O., & Kellerer, M. (2020) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1149-9030 · Cited by 4
Metformin in chronic kidney disease: a strong dose of caution
Hanna, R. M., Rhee, C. M., & Kalantar‐Zadeh, K. (2020) · Kidney International · doi:10.1016/j.kint.2020.04.060 · Cited by 5
[How I treat ... with metformin a diabetic patient with moderate renal insufficiency].
Scheen, A. J. (2013) · RMLG. Revue médicale de Liège · Cited by 10
Do colorectal cancer resections improve diabetes in long-term survivors? A case–control study
Faintuch, J., Hayashi, S. Y., Nahas, S. C., Yagi, O. K., Faintuch, S., & Cecconello, I. (2013) · Surgical Endoscopy · doi:10.1007/s00464-013-3273-0 · Cited by 4
Metformin: od mehanizmov delovanja do napredne klinične uporabe
Janić, M., Volčanšek, Š., Lunder, M., & Janež, A. (2017) · Slovenian Medical Journal · doi:10.6016/zdravvestn.1503 · Cited by 4
Linagliptin in the Management of Type 2 Diabetes Mellitus After Kidney Transplant
Attallah, N. M., & Yassine, L. (2021) · Transplantation Proceedings · doi:10.1016/j.transproceed.2021.07.035 · Cited by 4
Mortality and metformin use in patients with advanced chronic kidney disease
Lalau, J., Kajbaf, F., Arnouts, P., & Broe, M. E. D. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00285-5 · Cited by 4
Provider Decisions and Patient Outcomes After Premature Metformin Discontinuation
Bradley, J. N., Edwards, K. L., Gunter, J. T., Weideman, R. A., & Kelly, K. C. (2017) · Diabetes Spectrum · doi:10.2337/ds15-0049 · Cited by 3
Metformin in advanced chronic kidney disease: are current guidelines overly restrictive?
Cole, N. I., Swift, P. A., Suckling, R., & Andrews, P. (2016) · British Journal of Diabetes · doi:10.15277/bjd.2016.106 · Cited by 3
Metformin utilisation in Australian community and aged care settings
Huang, W., Peterson, G. M., Zaidi, S. T. R., & Castelino, R. L. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.01.041 · Cited by 4
Guelho, D., Paiva, I., & Carrilho, F. (2014) · Acta Médica Portuguesa · doi:10.20344/amp.4071 · Cited by 3
Diabetes and Kidney disease: metformin
Gnudi, L., & Ricciardi, C. A. (2022) · Springer eBooks · doi:10.1007/978-3-030-86020-2_24 · Cited by 3
Medication Pitfalls in the CKD Clinic: Case Presentations
Liles, A. M. (2014) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2014.03.014 · Cited by 2
Quesada, L., García, D. M., Martín, B. B., & Ferrando, J. P. (2016) · PubMed · Cited by 2
Metformina en enfermedad renal diabética: estado actual
Rodulfo, J. I. A., & Amair, P. (2017) · Revista Colombiana de Nefrología · doi:10.22265/acnef.4.2.255 · Cited by 3
Metformina y su rol en la enfermedad renal: estado del arte
Rico-Fontalvo, J. E., Daza-Arnedo, R., Raad-Sarabia, M., Pájaro-Galvis, N., Uparella-Gulfo, I., Corbacho, D. P., Pomares-Lara, A., Meza-Santiago, B., Montejo-Hernández, J. D., & Cardona-Blanco, M. (2022) · Nefrología Latinoamericana · doi:10.24875/nefro.21000046 · Cited by 2
Jairoun, A. A., Ping, C. C., Ibrahim, B., Jawamis, D. F. A., Jaberi, A. K. A., Dawoud, T. H., Mohammed, K. J., El‐Dahiyat, F., & Shahwan, M. J. (2024) · Journal of Pharmaceutical Policy and Practice · doi:10.1080/20523211.2024.2414293 · Cited by 2
Liu, X., Li, X., An, P., Gao, Q., Zhao, Y., Shi, X., & Wu, X. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2486551 · Cited by 3
My Patient's Diabetic Kidney Disease Has Progressed to Stage 4; Should I Discontinue Metformin?
Venos, E., & Sigal, R. J. (2014) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2014.07.225 · Cited by 2
Häufung schwerer Metformin-assoziierter Laktatazidosen
Rüegg, T., & Caduff, B. (2017) · DMW - Deutsche Medizinische Wochenschrift · doi:10.1055/s-0042-119280 · Cited by 3
Petrie, M. C., Boyle, J. G., & McKay, G. (2015) · Diabetic Medicine · doi:10.1111/dme.12709 · Cited by 2
Sobel, S. I., Brooks, H. E., Schwartz, R. S., & Kohrt, W. M. (2013) · Elsevier eBooks · doi:10.1016/b978-1-4557-4975-1.00065-6 · Cited by 2
Intoxicación por metformina: características clínicas, tratamiento y pronóstico
Galcerán, I., Escorihuela, C. R., Collado, S., Casanova, M. J. L., Pallàs, O., Campo, L. G., Crespo, M., & Supervía, A. (2025) · Nefrología · doi:10.1016/j.nefro.2025.501429 · Cited by 1
Metformin intoxication: clinical characteristics, treatment and prognosis
Galcerán, I., Escorihuela, C. R., Nieto, S. C., Casanova, M. J. L., Pallàs, O., Campo, L. G., Crespo, M., & Supervía, A. (2026) · Nefrología (English Edition) · doi:10.1016/j.nefroe.2026.501429 · Cited by 1
Metformin use and the risk of liver cancer in a Swedish population-based cohort study
Huang, Y., Santoni, G. B., Sparrelid, E., & Xie, S. (2026) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkag053 · Cited by 1
Further clarifying the relationship between metformin, acute kidney injury and lactic acidosis
Rhee, C. M., & Kalantar‐Zadeh, K. (2017) · Nature Reviews Nephrology · doi:10.1038/nrneph.2017.174 · Cited by 1
Moyad, M. A. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800077-9.00020-7 · Cited by 1
Metformin Challenges in Advanced Chronic Kidney Disease: A Promising Therapeutic Strategy
Díaz, M. F., Valente, R. A., Mosquera, V. B., Abuward, I., Martínez, S. P., Ardha, N., Beloso, M. D., García, D., Martínez, T. C., Carbajal, D. G., et al. (2017) · Cited by 1
Metformin misuse in chronic kidney disease
Coliche, V., Koppe, L., Laville, M., Nouvier, M., Pelletier, S., Trolliet, P., & Fouque, D. P. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.07.005 · Cited by 1
The role of metformin in the light of the most recent Guidelines
Corigliano, G. (2020) · The Journal of AMD · doi:10.36171/jamd20.23.1.07 · Cited by 1
Clinical Application of Metformin Use in Anhui Province, China: A Cross-Sectional Study
Chen, L., Chen, Q., Chen, X., Zhu, P., Chen, M., Wang, W., Ye, S., & Zheng, M. S. (2023) · Journal of Multidisciplinary Healthcare · doi:10.2147/jmdh.s397061 · Cited by 1
Rahmanian, M., Moradi, S., Fijani, M. R., Dehkordi, A. H., Dehghan, S., Ghanbarzadeh, E., Zaremoghadam, E., Mardanparvar, H., & Mohagheghi, S. Z. (2023) · Journal of Renal Endocrinology · doi:10.34172/jre.2023.25083 · Cited by 1
Mortality and metformin use in patients with advanced chronic kidney disease – Authors' reply
Hung, S., Chang, Y., Liu, J., Hsu, C.-C., & Tarng, D. (2015) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00287-9 · Cited by 1
Metformin in People With Diabetes and Advanced CKD: Should We Dare?
Shin, J., Créon, A., & Carrero, J. J. (2024) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2024.10.004 · Cited by 1
O uso de metformina em pacientes diabéticos com insuficiência renal. É tempo de mudança
de Almeida, F. A. (2015) · Revista da Faculdade de Ciências Médicas de Sorocaba · Cited by 1
Metformin, the remarkable and unique antidiabetic agent
Lakhdar, A. (2013) · Ibnosina Journal of Medicine and Biomedical Sciences · doi:10.4103/1947-489x.210551
Metadata
- Authors
- Ekström, N., Schiöler, L., Svensson, A.-M., Eeg-Olofsson, K., Miao Jonasson, J., Zethelius, B., Cederholm, J., Eliasson, B., & Gudbjörnsdottir, S.
- Affiliations
- University of Gothenburg (SE)
- Region Västra Götaland (SE)
- Department of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden
- Centre of Registers in Region Västra Götaland, Gothenburg, Sweden
- Uppsala University (SE)
- Corresponding author
- Ekström, Nils
- Venue
- BMJ Open
- Publisher
- BMJ
- Published
- 2012
- Volume
- 2
- Issue
- 4
- Pages
- e001076
- ISSN
- 2044-6055 (ISSN-L)
- PMC
- PMC3400073
- OpenAlex
- W2167639134
- Cited by
- 221
- References
- 39
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 10 · 2023: 7 · 2022: 12 · 2021: 24 · 2020: 19 · 2019: 19 · 2018: 13 · 2017: 26 · 2016: 18 · 2015: 18 · 2014: 29 · 2013: 13
- FWCI
- 15.40
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by-nc
- Locations
- BMJ Open (publishedVersion, cc-by-nc)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- HighWire Press Open Archive (submittedVersion)
- Funders
- Sveriges Kommuner och Landsting
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- metformin, type 2 diabetes, renal function, estimated glomerular filtration rate, cardiovascular disease, all-cause mortality, lactic acidosis, serious infections, sulfonylureas, insulin monotherapy, oral antidiabetic drugs, drug safety, treatment effectiveness, Swedish National Diabetes Register, propensity score adjustment, real-world clinical practice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
